An eEF1A1 truncation encoded by PTI-1 exerts its oncogenic effect inside the nucleus

Cancer Cell International

Charlotte R Knudsen¹  Ernst-Martin Füchtbauer¹  Karen Margrethe Nielsen¹  Liina Ränkel¹  Thomas J Corydon²  Louise D Dahl¹ 

[1] Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10C, 8000 Aarhus C, Denmark;Department of Biomedicine, Aarhus University, Aarhus C, Denmark

关键词: Translation elongation factor;    UTRs;    Localization;    Nucleus;    Oncogene;    PTI-1;   

Others  :  792321
DOI  :  10.1186/1475-2867-14-17

 received in 2013-09-16, accepted in 2014-02-20,  发布年份 2014

【 摘 要 】

Background

The oncogene PTI-1 was originally isolated from a prostate cancer cell line by its capability to transform rat fibroblasts. The PTI-1 mRNA has a very eccentric structure as the 5′UTR is similar to prokaryotic 23S rRNA, while the major open reading frame and the 3′UTR corresponds to a part of the mRNA encoding human translation elongation factor eEF1A1. Thus, the largest open reading frame encodes a truncated version of eEF1A1 lacking the first 67 amino acids, while having three unique N-terminal amino acids. Previously, the UTRs were shown to be a prerequisite for the transforming capacity of the PTI-1 transcript. In this study, we have investigated the possible role of the UTRs in regulating protein expression and localization.

Methods

The protein expression profiles of a number of PTI-1 mRNA variants were studied in vitro and in vivo. Furthermore, the oncogenic potentials of the same PTI-1 mRNAs were determined by monitoring the capacities of stably transfected cells expressing these mRNAs to induce tumors in nude mice and form foci in cell culture. Finally, the cellular localizations of PTI-1 proteins expressed from these mRNAs were determined by fluorescence microscopy.

Results

The PTI-1 mRNA was found to give rise to multiple protein products that potentially originate from translation initiation at downstream, inframe AUGs within the major open reading frame. At least one of the truncated protein variants was also found to be oncogenic. However, the UTRs did not appear to influence the amount and identities of these truncated protein products. In contrast, our localization studies showed that the UTRs of the transcript promote a nuclear localization of the encoded protein(s).

Conclusions

Translation of the PTI-1 mRNA results in multiple protein products of which (a) truncated variant(s) may play a predominant role during cellular transformation. The PTI-1 UTRs did not seem to play a role in translation regulation, but appeared to contribute to a nuclear localization of the PTI-1 protein(s). This indicates that the PTI-1 protein(s) exert(s) its/their oncogenic function inside the nucleus.

【 授权许可】

   
2014 Dahl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ejiri S: Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem 2002, 66:1-21.
• [2]Shen R, Su Z-Z, Olsson CA, Fisher PB: Identification of the human carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci USA 1995, 92:6778-6782.
• [3]Mansilla F, Hansen LL, Jakobsen H, Kjeldgaard NO, Clark BF, Knudsen CR: Deconstructing PTI-1: PTI-1 is a truncated, but not mutated, form of translation elongation factor 1A1, eEF1A1. Biochim Biophys Acta 2005, 1727:116-124.
• [4]Su Z-Z, Olsson CA, Zimmer SG, Fisher PB: Transfer of a dominant-acting tumor-inducing oncogene from human prostatic carcinoma cells to cloned rat embryo fibroblast cells by DNA-transfection. Anticancer Res 1992, 12:297-304.
• [5]Yu L, Wu G, Wang L, Wang H, Zhang G: Transient reduction of PTI-1 expression by short interfering RNAs inhibits the growth of human prostate cancer cell lines. Tohoku J Exp Med 2006, 209:141-148.
• [6]Gopalkrishnan RV, Su Z, Goldstein NI, Fisher PB: Translational infidelity and human cancer: role of the PTI-1 oncogene. Int J Biochem Cell Biol 1999, 31:151-162.
• [7]Lee M-H, Surh Y-J: eEF1A2 as a putative oncogene. Ann N Y Acad Sci 2009, 1171:87-93.
• [8]Su Z, Goldstein NI, Fisher PB: Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc Natl Acad Sci USA 1998, 95:1764-1769.
• [9]Pesole G, Mignone F, Gissi C, Grillo G, Licciulli F, Liuni S: Structural and functional features of eukaryotic mRNA untranslated regions. Gene 2001, 276:73-81.
• [10]Kozak M: An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 1991, 115:887-903.
• [11]Mignone F, Gissi C, Liuni S, Pesole G: Untranslated regions of mRNAs. Genome Biol 2002, 3:REVIEWS0004.
• [12]Dasso MC, Jackson RJ: On the fidelity of mRNA translation in the nuclease-treated rabbit reticulocyte lysate system. Nucleic Acids Res 1989, 17:3129-3144.
• [13]Kozak M: Evaluation of the fidelity of initiation of translation in reticulocyte lysates from commercial sources. Nucleic Acids Res 1990, 18:2828.
• [14]Scaggiante B, Bonin S, Cristiano L, Siracusano S, Stanta G, Dapas B, Giansante C, Fiotti N, Grassi G: Prostate tumor-inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma infection. Cancer Invest 2009, 26:800-808.
• [15]Vislovukh AA, Shalak VF, Savytskyi OV, Kovalenko NI, Gralievska NL, Negrutskii BS, El'skaya AV: PTI-1: novel way to oncogenicity. Biopolymers and Cell 2012, 28:404-410.
• [16]Donnelly C, Fainzilber M, Twiss JL: Subcellular communication through RNA transport and localized protein synthesis. Traffic 2010, 11:1498-1505.
• [17]Dalgleish G, Veyrune JL, Blanchard JM, Hesketh J: mRNA localization by a 145-nucleotide region of the c-fos 3′-untranslated region. J Biol Chem 2001, 276:13593-13599.
• [18]Mickleburgh I, Burtle B, Hollås H, Campbell G, Chrzanowska-Lightowlers Z, Vedeler A, Hesketh J: Annexin A2 binds to the localization signal in the 3′ untranslated region of c-myc mRNA. FEBS J 2005, 272:413-421.
• [19]Fan K, Chrzanowska-Lightowlers ZM, Hesketh JE: Fine mapping of interactions between eEF1alpha protein and 3′UTR of metallothionein-1 mRNA. Biochem Biophys Res Com 2009, 386:82-88.
• [20]Saunders C, Cohen RS: The role of oocyte transcription, the 5′UTR, and translation repression and derepression in Drosophila gurken mRNA and protein localization. Mol Cell 1999, 3:43-54.
• [21]Chartrand P, Meng XH, Singer RH, Long RM: Structural elements required for the localization of ASH1 mRNa and of a green fluorescent protein reporter particle in vivo. Curr Biol 1999, 9:333-336.
• [22]Minella O, Mulner-Lorillon O, De Smedt V, Hourdez S, Cormier P, Belle R: Major intracellular localization of elongation factor-1. Cell Mol Biol 1996, 42:805-810.
• [23]Kjær S, Wind T, Ravn P, Østergaard M, Clark BFC, Nissim A: Generation and epitope mapping of high-affinity scFv to eukaryotic elongation factor 1A by dual application of phage display. Eur J Biochem 2001, 268:3407-3415.
• [24]Billaut-Mulot O, Fernandez-Gomez R, Loyens M, Ouaissi A: Trypanosoma cruzi elongation factor 1-alpha: nuclear localiztaion in parasites undergoing apoptosis. Gene 1996, 174:19-26.
• [25]Gangwani L, Mikrut M, Galcheva-Gargova Z, Davis RJ: Interaction of ZPR1 with translation elongation factor-1alpha in proliferating cells. J Cell Biol 1998, 143:1471-1484.
• [26]Dapas B, Tell G, Scaloni A, Pines A, Ferrara L, Quadrifoglio F, Scaggiante B: Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers. Eur J Biochem 2003, 270:3251-3262.
• [27]Mishra AK, Gangwani L, Davis RJ, Lambright DG: Structural insight into the interaction of the evolutionary conserved ZPR1 domain tandem with eukaryotic EF1A, receptors, and SMN complexes. Proc Natl Acad Sci USA 2007, 104:13939-13935.
• [28]Leclercq TM, Moretti PAB, Vadas MA, Pitson SM: Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity. J Biol Chem 2008, 283:9606-9614.
• [29]Leclercq TM, Moretti PAB, Pitson SM: Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene 2011, 30:372-378.
• [30]Wattenberg BW: Role of sphingosine kinase localization in sphingolipid signaling. World J Biol Chem 2010, 1:362-368.
• [31]Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S: Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003, 278:46832-46839.
• [32]Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, Milstien S, Spiegel S: Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 2003, 278:40330-40336.
• [33]Okada T, Ding G, Sonoda H, Kajimoto T, Haga Y, Khosrowbeygi A, Gao S, Miwa N, Jahangeer S, Nakamura S: Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem 2005, 280:36318-36325.
• [34]Nguyen TLX, Choi JW, Lee SB, Ye K, Woo SD, Lee KH, Ahn JY: Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells. Biochem Biophys Res Com 2006, 349:789-798.
• [35]Maddika S, Bay GH, Kroczak TJ, Ande SR, Maddika S, Wiechec E, Gibson SB, Los M: Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif 2007, 40:835-848.
• [36]Los M, Maddika S, Erb B, Schulze-Osthoff K: Switching Akt: from survival signalign to deadly reponse. BioEssays 2009, 31:492-495.
• [37]Lau J, Castelli LA, Lin E, Macaulay SL: Identification of elongation factor 1alpha as a potential associated binding partner for Akt2. Mol Cell Biochem 2006, 286:17-22.
• [38]Pecorari L, Marin O, Silvestri C, Candini O, Rossi E, Guerzoni C, Cattelani S, Mariani SA, Corradini F, Ferrari-Amorotti G, Cortesi L, Bussolari R, Raschella G, Federico MR, Calabretta B: Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Mol Cancer 2009, 8:58. BioMed Central Full Text
• [39]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [40]Faerch M, Christensen JH, Rittig S, Johansson JO, Gregersen N, de Zegher F, Corydon TJ: Diverse vasopressin V2 recpetor functionality underlying partical congenital nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2009, 297:F1518-F1525.